natgillin/translations-raw huggingface dataset:
Even in a more preferred embodiment, the organic solvent is selected form methanol, toluene, xylene, acetone, ethyl acetate, acetonitrile, tetrahydrofuran, isopropyl acetate, ethyl formiate, methyl tertbutyl ether, diethylcarbonate, chlorobenzene, dichloromethane and mixtures thereof. 
Postupak u skladu s patentni zahtjevi 7 ili 8, naznačen time što se organsko otapalo bira između metanola, toluena, ksilena, acetona, etil-acetata, acetonitrila, tetrahidrofurana, izopropil-acetata, etil-formijata, metil-rerr-butil-etera, dietil-karbonata, klorbenzena, diklormetana i njihovih smjesa.
Some of the compounds of the invention can be prepared from other compounds of the invention by conventional techniques, e.g. 
Neki spojevi iz izuma mogu se načiniti iz drugih spojeva iz izuma konvencionalnim tehnikama, npr.
Spraying said aqueous suspension on granules of a fumaric acid ester for a period of time sufficient to obtain a uniform coating thereon; Drying the granules obtained; 
HR P20130480 T1 b) raspršivanje spomenute vodene otopine na granule estera fumarne kiseline u vremenskom razdoblju dovoljnom za dobivanje jednolične obloge na njima;
and pharmaceutically acceptable enantiomers, diastereomers, racemates, and salts thereof, optionally wherein 
i njihovi farmaceutski prihvatljivi enantiomeri, diastereomeri, racemati i soli.
Said hemangioblasts may be cultured on said matrix for at least about 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days. Said hemangioblasts may be differentiated from pluripotent cells. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 5-7, naznačen time što se hemangioblaste uzgaja na matriksu najmanje otprilike 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 ili 30 dana.
In one embodiment, R3 is selected from the group consisting of 
R, je odabran iz skupine koja sadrži (1) vodik,
The construct for the use of claim 6, wherein administration is intravenous or subcutaneous, parenteral, transdermal, intraperitoneal, intramuscular or pulmonary. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što je primjena intravenska ili supkutana, parenteralna, transdermalna, intraperitonealna, intramuskularna ili pulmonalna.
is individually and independently selected from the group consisting of Leu, Ile, Val, Met, Trp, Tyr and Phe; is individually and independently selected from the group consisting of Ser, Thr, Ala and Gly; and/or 
€) x3ili Xxx, se pojedinačno i neovisno bira iz skupine koju čine Leu, Ile, Val, Met, Trp, Tyr i Phe; iili d) xaili Xxx4 se pojedinačno i neovisno bira iz skupine koju čine Ser, Thr, Ala i Gly.
A modified soluble FGF receptor Fc fusion of claim 26 wherein said chemotherapeutic agent is selected from the group: anti-microtubule agents; platinum coordination complexes; alkylating agents; antibiotic agents; topoisomerase II inhibitors; antimetabolites; topoisomerase I inhibitors; hormones and hormone analogues; signal transduction pathway inhibitors; non-receptor tyrosine kinase angiogenesis inhibitors; immunotherapeutic agents; pro-apoptotic agents; and cell cycle signaling inhibitors. 
Modificirana fuzija između topivog FGF receptora i Fc u skladu s patentnim zahtjevom 33, naznačena time što navedeno kemoterapijsko sredstvo se bira iz skupine koju čine antimikrotubularna sredstva, platinski koordinacijski kompleksi, alkilacijska sredstva, antibiotička sredstva, inhibitori topoizomeraze II; antimetaboliti, inhibitori topoizomeraze I, hormoni i hormonski analozi, inhibitori puteva prijenosa signala, inhibitori nereceptorske angiogene tirozin-kinaze, imunoterapijska sredstva, proapoptotska sredstva, te inhibitori signalizacije staničnog ciklusa.
The fibre composition will selectively promote the proliferation of beneficial bacteria, which in turn will prevent the proliferation of harmful and/or spoilage bacteria. 
Sastavina vlakana selektivno će pospješiti proliferaciju korisnih bakterija, čime će se pak spriječiti proliferacija štetnih bakterija i/ili bakterija koje uzrokuju kvarenje.
The hot steam always remains in the thermoblock 10 such that hot steam is always avaialble on demand. The thermoblock 10 will only be vented at the start of its operation. This is to avoid that any liquid sucked-in and condensed inside the thermoblock 10 after the cooling-down once the thermoblock 10 is switched off will produce unwanted excess steam. 
Vruća vodena para uvijek ostaje u termobloku 10, tako da je vruća vodena para uvijek dostupna na zahtjev. Termoblok 10 propuhuje se samo na početku svog rada, Treba izbjeći da se iz bilo koje količine tekućine koja je usisana i kondenzirana u termobloku 10 nakon hlađenje kada se termoblok 10 isključi dobije neželjen suvišak vodene pare.
This separation may take place either at the level of a starting compound or in a compound of formula (Ia) itself. 
To rastavljanje se može izvršiti još s polaznim spojem ili sa samim spojem formule (1) ili (Ia).
The process of any preceding claim, further comprising a step of: addition of mannitol. 
Proces prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da nadalje sadrži stupanj dodavanja manitola.
Method for producing a low-carbon clinker according to any one of the preceding claims, characterized in that the silico-aluminous materials are selected from blast furnace slag, clays, marl clays, shale. 
Postupak za proizvodnju klinkera s niskim udjelom ugljika u skladu s patentnim zahtjevom 1, naznačen time što su silikatno aluminatni materijali odabrani od šljake iz visoke peći, glina, lapornih glina, škriljevca.
A compound according to claim 1 or 2, wherein Q is hydrogen. 
Tvar u skladu s patentnim zahtjevom 1 ili 2, pri čemu je Q vodik.
The compound of claim 1, which is: 
Spoj sukladno zahtjevu 1, s formulom:
Crystalline form 1 of atorvastatin tert.-butyl ester of the formula (II) characterized by an X-ray powder diffraction pattern having peaks at: 6.10, 6.83, 10.77, 17.01 ± 0.1 degrees two-theta. 
Kristalni oblik 1 fert-butilnog estera atorvastatina formule (IT) naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu, sa signalima na: 6,10, 6,83, 10,77, 17,71 +
The method of claim 8, wherein the statistical distribution is further dependent on the number of the plurality of nucleic acid molecules corresponding to the specific locus. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što statistička raspodjela dodatno ovisi o broju skupina molekula nukleinske kiseline koje odgovaraju specifičnom lokusu.
Na2SO4 (13g) was added to the mixture and it was filtered through filter paper. 
NaoSO, (13 g) je bio dodan smjesi i filtriran kroz papir za filtriranje.
Capsule according to any of claims 1 to 5, characterized in that the total displacement of the actuation element (5; 5e, 5s) and/or the volume of the accumulation chamber (6), preferentially respective interior height, are previously defined as a function of at least one type of aromatic substance, or of the dimension of the grain of said substance or of the interior volume of the capsule {1, 1'}. 
Kapsula u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da je ukupni pomak elementa za pokretanje (5; 5e, 5s) i / ili volumena akumulacijske komore (6), poželjno unutarnja visina, unaprijed definiran kao funkcija najmanje jedne vrste aromatskih tvari ili veličine zrna navedene tvari ili unutarnjeg volumena kapsule (1, 1').
an effective amount of borate, the effective amount being at least 0.05 w/v% and less than 0.5 w/v% of the overall composition; 
učinkovitu količinu borata, te je učinkovita količina borata najmanje 0,05 m/v% ali manja od 0,5 m/v% ukupnog pripravka;
Presently venlafaxine hydrochloride is admistered to adults as conventional immediate release tablets or as 24 hour extended release multiparticulate capsules. 
Trenutno se venlafaksin-hidroklorid primijenjuje na odraslima kao konvencionalne tablete s trenutnim otpuštanjem ili kao multipartikularne kapsule 24-satnim produljenim otpuštanjem.
The wear member according to claim 1 or 2, characterized in that each of the transverse, inward projections extends from the front thrust surface (152) and substantially along an entire length of the socket (120). 
Potrošni element u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se svaka od poprečnih izbočina koje se pružaju prema unutra pruža od prednje potisne površine (152) i uglavnom po cijeloj duljini šupljine (120).
This was collected by filtration and was washed with industrial methylated spirits. The solid was crystallised from industrial spirits (430 ml) and dried at 55° to give the title compound (38.4 g) as a white solid confirmed spectroscopically to be identical with the products of Examples 9 and 12. 
Ovaj se sakupi filtracijom 1 ispere s industrijskim metiliranim alkoholima, čvrsta supstanca se Tekristalizira iz industrijskih metiliranih alkohola (430 ml) i suši na 55* tako da se dobija naslovni spoj (38,4 g) kao bijela čvrsta supstanca koja je na osnovi spektroskopije dokazana da je identična proizvodima iz primjera 9 i 12.
An isolated polypeptide of claim 1, wherein the polypeptide is an anti-STAT3 single domain antibody (sdAb), wherein the anti-STAT3 sdAb comprises the amino acid sequence as set forth in SEQ ID NO:3. 
Izolirani polipeptid prema patentnom zahtjevu 1, naznačen time što je polipeptid anti-STAT3 antitijelo s jednom domenom (sdAb), pri čemu anti-STAT3 sdAb sadrži aminokiselinsku sekvencu kao što je navedena u SEQ ID NO:3.
After dilution with 3.6 L of toluene, the mixture was cooled to 0-5° C. prior to cautiously adding 7 L of H2O at a rate such that the temperature did not exceed 10° C. Note a severe exotherm results upon addition of the first portion of H2O. 
Poslije razblažavanja sa 3.61 toluena, smjesa je hlađena do 0-5*C prije pažljivog dodavanja 71 H2O takvom stopom da temperatura nije prešla 10%C. Obratiti pažnju na to da se javlja snažna egzotermna reakcija uslijed dodavanja prvog dijela H2O.
A method according to claim 1, wherein in the compound of formula (I) ring B and the pyrimidine to which it is fused form a ring system selected from the group consisting of 
Spoj prema zahtjevu 1, 2 ili 3 naznačen time da prsten B i pirimidin na koji je kondenziran tvore prstenasti sustav odabran od
The dsRNA for use of claim 20, wherein the additional therapeutic method is selected from the group consisting of diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, dialysis, and a liver transplant. 
dsRNA za uporabu prema zahtjevu 13 ili 14, naznačena time da čovjek dodatno prima terapijski postupak za liječenje TTR amiloidoze, te je terapijski postupak odabran iz skupine koja sadrži diuretike, inhibitore angiotenzin pretvarajućeg enzima, blokatore receptora angiotenzina, dijalizu, ili transplantaciju jetre.
RA and RB are independently selected from the group consisting of hydrogen, alkyl, and alkylcarbonyl; and RC and RD are independently selected from the group consisting of hydrogen and alkyl. 
R4 je odabran iz skupine koja se sastoji od vodika, alkila, arilalkila, cikloalkila, cikloalkilalkila, heterocikla, heteroarilalkila i (NRcRp)sulfonila; i
determining, at each of the ten grid crossings, the austenite phase length/width ratio by measuring the length and the width of the austenite phase, wherein the length is the longest uninterrupted distance when drawing a straight line between two points at the phase boundary, the phase boundary being the transition from an austenitic phase to the ferrite phase; and wherein the width is defined as the longest uninterrupted distance measured perpendicular to the length in the same phase; 
Određivanje, na svakom od deset sjecišta, omjera duljine 1 širine austenitne faze mjerenjem njezine duljine 1 širine, pri čemu duljina označava najveću neprekidnu udaljenost kad se povuče ravna crta između dvije točke na granici faze, s tim da granica predstavlja prijelaz iz austenitne u feritnu fazu; i pri čemu se širina određuje kao najveća neprekidna udaljenost izmjerena okomito na duljinu u istoj fazi; izračunavanje prosječnog omjera duljine i širine austenitne faze iz deset izmjerenih omjera njezine duljine i širine.
Use or HfO2 nanoparticles or HfO2 nanoparticles' aggregates for use according to claim 13, wherein said malignant cells are cells from a tumor selected in the group consisting of a haematological tumor and a solid tumor. 
Uporaba ili nanočestice HfO, ili agregati nanočestica HfO> za uporabu prema zahtjevu 13, gdje su spomenute maligne stanice stanice od tumora odabranog iz skupine koju čine hematološki tumor i solidni tumor.
WO00/53182 proposes the use of roflumilast or its N-oxide for the treatment of multiple sclerosis. 
WO00/53182 predlaže uporabu roflumilasta ili njegovog N-oksida za liječenje multiple skleroze.
If the compounds of the Formula (I) or pharmaceutical compositions comprising them are administered as aerosols, for example as nasal aerosols or by inhalation, this can be carried out, for example, using a spray, a nebulizer, a pump nebulizer, an inhalation apparatus, a metered inhaler or a dry powder inhaler. 
Ukoliko se spojevi Formule (D) ili farmaceutski pripravci koji ih sadrže primjenjuju kao aerosoli, na primjer kao nazalni aerosoli ili putem inhalacija, to se može provesti uporabom spreja, nebulizatora, pump nebulizatora, inhalatora, mjernog inhalatora ili inhalatora sa suhim prahom.
From this and from the structural similarity to TLK117, TLK199, and related compounds, the compounds are therefore expected to act therapeutically to: potentiate the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exert cytotoxicity in tumor cells, elevate the production of GM progenitors in bone marrow, stimulate the differentiation of bone marrow, mitigate the myelosuppressive effects of chemotherapeutic agents, and modulate hematopoiesis in bone marrow. 
Također su aktivni u pojačavanju diferencijacije HL-60 stanica in vitro, i jedan je pokazao pojačanu formaciju granulocit/monocit stanične kolonije iz koštane srži murine ex vivo, Iz ovih i iz strukturalno sličnih TLK 117, TLK 199, i odgovarajućih spojeva, očekuje se da spojevi iz ovog izuma djeluju terapeutski na čovjeka: pojačavaju citotoksični efekt kemoterapeutskih agensa u stanicama tumora, pokazuju selektivni citotoksicitet u stanicama tumora, podižu produkciju GM progenitora u koštanoj srži, stimuliraju diferencijaciju stanica koštane srži, ublažuju mielosupresivne efekte kemoterapijskih agensa i moduliraju hematopoiesis u koštanoj srži.
The method of claim 1, wherein the CD8a hinge domain comprises the amino acid sequence of SEQ ID NO: 21. The method of claim 1, wherein the CD3 zeta signaling domain comprises the amino acid sequence of SEQ ID NO: 24. The method of claim 6, wherein the scFv is encoded by a nucleic acid sequence comprising SEQ ID NO: 14. 
(i) - kostimulatorno signalno područje 4-1 BB sadrži aminokiselinsku sekvencu naznačenu u SEQ ID NO: 23; (11) CAR sadrži aminokiselinsku sekvencu naznačenu u SEQ ID NO: 12; (ili) anti-CD19 scFv je kodirano sekvencom SEQ ID NO: 14;
magnesium stearate is present in a total amount of 0.1% to 2% by weight based on total weight of the tablet; the coating comprises a functional or non-functional polymer. 
najmanje jedan lubrikant u ukupnoj količini od manje od 0,1 do dva masena postotka na osnovi ukupne mase tablete, gdje taj lubrikant je magnezijev stearat; i
was stirred at reflux for 36 hours and then cooled to room temperature. 
miješa se na refluksu 36 sati 1 tada se ohladi na sobnu temperaturu.
Moreover, the bonding spots and/or bonding areas may be arranged side-by-side and separated from each other in the horizontal direction within the contact path. 
Osim toga, točke spajanja i/ili područja spajanja mogu biti raspoređeni jedni uz druge i odvojeni jedni od drugih u horizontalnom i/ili u vertikalnom smjeru unutar staze za kontakte.
The combination for use as claimed in claim 1, wherein the carbonic anhydrase inhibitor is dorzolamide. 
Kombinacija za uporabu u skladu s patentnim zahtjevom 1, pri čemu je inhibitor karboanhidraze dorzolamid.
The oral solid pharmaceutical composition according to any of the preceding claims, wherein the particle size (d10) of the Lenalidomide particles is of from 0.1µm to 2µm, preferably from 0.05µm to 1µm, even more preferably from 0.08µm to 0.7µm and most preferred from 0.1µm to 0.4µm. 
Oralni kruti farmaceutski sastav prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da raspodjela čestica po veličini (d10) čestica Lenalidomida jest od 0,1 µm do 2 µm, pogodno od 0,05 µm do 1 µm, čak pogodnije od 0,08 µm do 0,7µm i najpogodnije od 0,1 µm do 0,4 µm.
is selected from H and R, or if Q is O, then R11 is SO3M, where M is a metal cation; R and R′ are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; 
R" jeili Hili R, ili SOM kada Q je O, gdje M je metalni kation, poželjno gdje R'' je H; svaki od R i R' neovisno je odabran od sljedećih opcijski supstituiranih skupina: Cr12-alkil, C320-heterociklil 1 Cs5.20-aril, i po izboru u odnosu na skupinu NRR', R i R' zajedno s dušikovim atomom na kojega su priključeni, tvore po izboru supstituirani 4-člani, 5-člani, 6-člani ili 7-člani heterociklički prsten;
the composition comprises a single strain of the genus Blautia; and/or 
(6) kompozicija obuhvaća jednu vrstu iz roda Blautia; ifili
The child-resistant blister pack (1) as claimed in claim 1, wherein the blister film sheet (7) is transparent. 
Blister pakiranje koje djeca ne mogu otvoriti (1) kako se navodi u patentnom zahtjevu 1, naznačeno time, da je tankoslojna blister folija (7) prozirna. t>&
The contents of the flask were placed in a nitrogen environment and 10mL anhydrous DCM added to the flask. 
Sadržaj tikvice je bio stavljen u prostor s dušikom i u tikvicu je bilo dodano 10 mL bezvodnog DCM.
The process of item 39, wherein the opioid analgesic is oxycodone hydrochloride and the dosage form comprises from about 5 mg to about 500 mg of oxycodone hydrochloride. 
Postupak prema zahtjevu 39, naznačen time da je opioidni analgetik oksikodon hidroklorid i da oblici davanja sadrže od oko 5 mg do oko 500 mg oksikodon hidroklorida.
The pharmaceutical composition of Claim 45, wherein Y1 is an optionally substituted phenyl, an optionally substituted pyridyl, an optionally substituted thiophenyl, [1,2,3]thiadiazolyl, an optionally substituted isoxazolyl, 1 H -pyrazolyl, quinolinyl, imidazolyl, or 2,3-dihydrobenzo[1,4]dioxine. 
Farmaceutski pripravak prema zahtjevu 45, naznačen time da Y1 je opcijski supstituiran fenil, opcijski supstituiran piridil, opcijski supstituiran tiofenil, [1,2,3]tiadiazolil, opcijski supstituiran izoksazolil, 1H-pirazolil, kvinolinil, imidazolil, ili 2,3-dihidrobenzo[1,4]dioksin.
Compounds of formula X and XI have R1—R9, R′, and G as described previously. 
Spojevi formule X i XI sadrže R'-R*, R! i G prema gornjem opisu.
A method of treating a disease or condition selected from the group consisting of psoriasis, inflammatory skin conditions, onychomycosis, skin cancer, abnormal keratinization induced diseases, skin aging, pustulardermatosis, and CTCL in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 10 . 
Rafinirani ekstrakt u skladu s bilo kojim od patentnih zahtjeva 3 do 9, naznačen time što je namijenjen upotrebi u liječenju bolesti ili stanja kojeg se bira iz skupine koju čine psorijaza, upalna stanja kože, onihomikoza, rak kože, bolesti uzrokovane abnormalnim keratiniziranjem, starenje kože, pustozna dermatoza, te CTCL.
greater than about 100 nucleotides in length. The nanoparticle of claim 5, wherein the molar ratio of the cargo molecule to the peptide in the nanoparticle is from about 1:1 to about 1:80, optionally wherein the molar ratio of the cargo molecule to the peptide in the nanoparticle is from about 1:5 to about 1:40; 
Nanočestica prema patentnom zahtjevu 6 ili 7, pri čemu je a) molarni omjer molekule tereta 1 peptida u nanočesticama je od oko 1:1 do oko 1:80, pri čemu je molarni omjer molekule tereta i peptida u nanočesticama opcijski od oko 1:5 do oko 1:40; b) molekula tereta je složena sa skupnom molekulom kako bi formirala jezgru nanočestice, pri čemu se skupna molekula opcijski odabire iz skupine koja se sastoji od peptida, proteina, antitijela, lipida, fosfolipida, polimera, aptamera, nanočestica, liposoma, dendrimera, polimerosoma, virusnog vektora i micele;
Analysis of the pravastatin salt by HPLC determined that the impurity pravastatin C was present in an amount of 0.12% by weight. 
Analiza soli pravastatina HPLC-om utvrdila je prisutnost onečišćenja pravstatin C u količini od 0.12% težine. HR P20080686 T3
A formulation comprising an aqueous carrier having a pH of 5.5 to 8.0 and a polypeptide comprising one or more single variable domains at a concentration of 1 mg/mL to 200 mg/mL, said formulation being formulated for administration to a human subject and said formulation further comprising a histidine buffer at a concentration of lOmM to 100mM, pH 6.0-6.5; wherein said formulation has an inorganic salt concentration of 150 mM or lower, wherein the polypeptide is selected from one of SEQ ID NO's: 1 to 6 and wherein the pH of the formulation is between 6.2 and 7.5. 
Formulacija koja sadrži vodeni nosač koji ima pH od 5.5 do 8.0 i polipeptid koji sadrži jednu ili više pojedinačnih varijabilnih domena u koncentraciji od 1 mg/mL do 200 mg/mL, navedena formulacija formulirana je za davanje ljudskom subjektu i navedena formulacija nadalje sadrži histidinski pufer u koncentraciji od 10 mM do 100 mM, pH 6.0-6.5; pri čemu navedena formulacija ima koncentraciju anorganske soli od 150 mM ili nižu, pri čemu je polipeptid odabran od jedne od SEQ ID NO: 1 do 6 i pri čemu pH formulacije iznosi između 6.2 i 7.5.
wherein the compound is of Formula (I'-a): or a pharmaceutically acceptable salt thereof; or wherein the compound is of Formula (I'-b): or a pharmaceutically acceptable salt thereof. 
pri čemu je spoj s Formulom (I'-a): ili njegova farmaceutski prihvatljiva sol; ili pri čemu je spoj s Formulom (I'-b): ili njegova farmaceutski prihvatljiva sol.
Statement 41. A metered dose inhaler according to statement 40, wherein the metered dose inhaler dispenses the co-suspension at an initial fine particle fraction and the initial fine particle fraction dispensed from the metered dose inhaler is substantially maintained, such that, throughout emptying of the canister, the fine particle fraction delivered from the metered dose inhaler is maintained within 80% of the initial fine particle fraction. 
Inhalator za odmjerene doze u skladu s patentnim zahtjevom 14, naznačen time što inhalator za odmjerene doze izdaje ko-suspenziju u početnoj frakciji finih čestica, gdje se početnu frakciju finih čestica izdanu iz inhalatora za odmjerene doze uglavnom održava, tako da se, tijekom pražnjenja spremnika, frakciju finih čestica unesena iz inhalatora za odmjerene doze održava unutar 80% od početne frakcije finih čestica, unutar 90% od početne frakcije
The method according to claim 4, wherein the quantification of the level of IGFBP2 protein is performed by using a set of antibodies directed against IGFBP2. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što se kvantificiranje razine proteina IGFBP2 provodi uz pomoć kompleta protutijela usmjerenih protiv IGFBP2.
The 3,11b- cis -dihydrotetrabenazine Isomer D used in the invention may be in substantially pure form, for example at an isomeric purity of greater than 90%, typically greater than 95% and more preferably greater than 98%. 
Cis-dihidrotetrabenazin Izomer A koji se koristio u izumu može biti u gotovo čistom obliku, na primjer u izomernoj čistoći većoj od 90%, obično većoj od 95% te je posebno povoljno kada je čistoća veća od 98%.
The method according to claim 1, wherein the ratio of acetic acid to zeolite is about 7 to 35% by weight. The method according to claim 1, wherein said zeolite is a basic zeolite. 
Pripravak prema zahtjevu 7, naznačen time što je omjer octene kiseline prema zeolitu od 7 to 35% težinski, najpoželjnije od 10 do 34%, kao što je od 13 do 33%.